



Boehringer Ingelheim is a research-driven pharmaceutical group of companies dedicated to serving humankind by researching, developing, manufacturing and marketing pharmaceuticals that improve health and quality of life. The focus is on the production of innovative drugs and treatments that represent major therapeutic advances. Boehringer Ingelheim employs 6,400 highly qualified people working in research & development out of almost 40,000 Boehringer Ingelheim employees worldwide. Boehringer Ingelheim's drug discovery focuses on seven major therapeutic areas: cardiovascular diseases, central nervous system (CNS) diseases, immunology & inflammation, metabolic diseases, oncology, respiratory diseases and virology. Two departments are involved. The Department of Non-Clinical Drug Safety is responsible for the toxicological assessment of new compounds during their development and on the market. The BI Clinical Biomarker Unit within the Dept of Drug Metabolism and Pharmacokinetics coordinates the analysis of BMs in the global clinical development programmes of Boehringer Ingelheim and supports the organisation in selection of potential relevant BMs, set-up and validation of analytical methods and realisation of biomarker analyses in clinical trials.

www.boehringer-ingelheim.com